| Juliana Elizabeth Wilson, | |
|
12605 E 16th Ave, Aurora, CO 80045-2545 | |
| (720) 848-0000 | |
| Not Available |
| Full Name | Juliana Elizabeth Wilson |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 15 Years |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205061975 | NPI | - | NPPES |
| 53875524 | Medicaid | CO | |
| P01401644 | Other | CO | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 262898-1 (New York) | Secondary |
| 207P00000X | Emergency Medicine | DR.0053726 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Colorado Hospital Authority | Aurora, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The Tuttlingen medical technology company Aesculap AG has founded the Freiburg startup neuroloop GmbH in cooperation with the University of Freiburg and the Freiburg University Medical Center. Building on research work from a team led by Prof. Dr. Thomas Stieglitz at the university's Department of Microsystems Engineering (IMTEK) and a research group at the university medical center, the company plans to develop neurostimulators that will be capable among other things of lowering high blood pressure.
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
Under a voluntary resolution agreement reached with the U.S. Department of Health and Human Services (HHS), deaf or hard-of-hearing patients at the Mid-Maryland Musculoskeletal Institute (MMI) of Frederick, Md., will be screened and provided with sign language interpreters whenever interpreter services are necessary for effective communication. MMI is an 11-physician orthopedic practice with offices in Frederick and Hagerstown, Md., serving approximately 1,000 patients per month.
Per capita consumption of ethanol derived from sales of beer, wine and spirits is the most comprehensive and reliable measure of a population's overall alcohol-drinking behaviors.
› Verified 4 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The Tuttlingen medical technology company Aesculap AG has founded the Freiburg startup neuroloop GmbH in cooperation with the University of Freiburg and the Freiburg University Medical Center. Building on research work from a team led by Prof. Dr. Thomas Stieglitz at the university's Department of Microsystems Engineering (IMTEK) and a research group at the university medical center, the company plans to develop neurostimulators that will be capable among other things of lowering high blood pressure.
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
Under a voluntary resolution agreement reached with the U.S. Department of Health and Human Services (HHS), deaf or hard-of-hearing patients at the Mid-Maryland Musculoskeletal Institute (MMI) of Frederick, Md., will be screened and provided with sign language interpreters whenever interpreter services are necessary for effective communication. MMI is an 11-physician orthopedic practice with offices in Frederick and Hagerstown, Md., serving approximately 1,000 patients per month.
Per capita consumption of ethanol derived from sales of beer, wine and spirits is the most comprehensive and reliable measure of a population's overall alcohol-drinking behaviors.
› Verified 4 days ago
| Entity Name | Carepoint Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275516346 PECOS PAC ID: 0547154957 Enrollment ID: O20040209000313 |
News Archive
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The Tuttlingen medical technology company Aesculap AG has founded the Freiburg startup neuroloop GmbH in cooperation with the University of Freiburg and the Freiburg University Medical Center. Building on research work from a team led by Prof. Dr. Thomas Stieglitz at the university's Department of Microsystems Engineering (IMTEK) and a research group at the university medical center, the company plans to develop neurostimulators that will be capable among other things of lowering high blood pressure.
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
Under a voluntary resolution agreement reached with the U.S. Department of Health and Human Services (HHS), deaf or hard-of-hearing patients at the Mid-Maryland Musculoskeletal Institute (MMI) of Frederick, Md., will be screened and provided with sign language interpreters whenever interpreter services are necessary for effective communication. MMI is an 11-physician orthopedic practice with offices in Frederick and Hagerstown, Md., serving approximately 1,000 patients per month.
Per capita consumption of ethanol derived from sales of beer, wine and spirits is the most comprehensive and reliable measure of a population's overall alcohol-drinking behaviors.
› Verified 4 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The Tuttlingen medical technology company Aesculap AG has founded the Freiburg startup neuroloop GmbH in cooperation with the University of Freiburg and the Freiburg University Medical Center. Building on research work from a team led by Prof. Dr. Thomas Stieglitz at the university's Department of Microsystems Engineering (IMTEK) and a research group at the university medical center, the company plans to develop neurostimulators that will be capable among other things of lowering high blood pressure.
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
Under a voluntary resolution agreement reached with the U.S. Department of Health and Human Services (HHS), deaf or hard-of-hearing patients at the Mid-Maryland Musculoskeletal Institute (MMI) of Frederick, Md., will be screened and provided with sign language interpreters whenever interpreter services are necessary for effective communication. MMI is an 11-physician orthopedic practice with offices in Frederick and Hagerstown, Md., serving approximately 1,000 patients per month.
Per capita consumption of ethanol derived from sales of beer, wine and spirits is the most comprehensive and reliable measure of a population's overall alcohol-drinking behaviors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Juliana Elizabeth Wilson, Po Box 110429, Aurora, Co 80042-0429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Juliana Elizabeth Wilson, 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The Tuttlingen medical technology company Aesculap AG has founded the Freiburg startup neuroloop GmbH in cooperation with the University of Freiburg and the Freiburg University Medical Center. Building on research work from a team led by Prof. Dr. Thomas Stieglitz at the university's Department of Microsystems Engineering (IMTEK) and a research group at the university medical center, the company plans to develop neurostimulators that will be capable among other things of lowering high blood pressure.
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
Under a voluntary resolution agreement reached with the U.S. Department of Health and Human Services (HHS), deaf or hard-of-hearing patients at the Mid-Maryland Musculoskeletal Institute (MMI) of Frederick, Md., will be screened and provided with sign language interpreters whenever interpreter services are necessary for effective communication. MMI is an 11-physician orthopedic practice with offices in Frederick and Hagerstown, Md., serving approximately 1,000 patients per month.
Per capita consumption of ethanol derived from sales of beer, wine and spirits is the most comprehensive and reliable measure of a population's overall alcohol-drinking behaviors.
› Verified 4 days ago
Dr. Timothy Owen Vanderkooy, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 13123 E 16th Ave, Aurora, Co 80045-7106, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Douglas K Hammond, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2550 S Parker Rd, Ste 206, Aurora, CO 80014 Phone: 303-306-7783 Fax: 303-306-7753 | |
Barbara Blok, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Charles Little, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Stephan Schrager, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Dr. William R Abbott, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3033 S Parker Rd, Ste 800, Aurora, CO 80014 Phone: 303-306-7783 Fax: 303-306-7753 | |
Michael Jobin, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |